Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cpi 613 SCHEMBL13333201 | 1.00 | CYP2C19 (0.59) | CYP2C19MAPTRXFP1PTGER1PTGER4 | |
| SCHEMBL17381514 | 0.99 | CYP2C19 (0.58) | CYP2C19MAPTRXFP1PTGER1PTGER4 | |
| SCHEMBL22299081 | 0.99 | CYP2C19 (0.58) | CYP2C19MAPTRXFP1PTGER1PTGER4 | |
| SCHEMBL10307745 | 0.92 | CYP2C19 (0.50) | CYP2C19PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL20395792 | 0.91 | CYP2C19 (0.63) | CYP2C19MAPTRXFP1PTGER1PTGER4 | |
| SCHEMBL10307777 | 0.91 | CYP2C19 (0.52) | CYP2C19MAPTRXFP1PTGER1PTGER4 | |
| SCHEMBL13333202 | 0.90 | CYP2C19 (0.50) | CYP2C19PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL28677430 | 0.90 | CYP2C19 (0.48) | CYP2C19MAPTRXFP1PTGER1PTGER4 | |
| Cpi 613 SCHEMBL26613507 | 0.89 | CYP2C19 (0.54) | CYP2C19MAPTRXFP1PTGER1PTGER4 | |
| SCHEMBL16375392 | 0.89 | CYP1A2 (0.50) | CYP2C19MAPTRXFP1PTGER1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 779 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| EP-4640714-A2 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| EP-3297613-B1 | MESOSCALE NANOPARTICLES FOR SELECTIVE TARGETING TO THE KIDNEY AND METHODS OF THEIR THERAPEUTIC USE | UNIV CITY NEW YORK RES FOUND (US) | 2025-09-03 | — | — | EP | claimed |
| EP-4608430-A1 | TREATMENT OF PROSTATE CANCER BY PROMOTING PDE4D7 | Koninklijke Philips N.V. (NL) | 2025-09-03 | — | — | EP | claimed |
| US-12350247-B2 | Use of APE1/Ref-1 inhibitors for treatment of retinal diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2025-07-08 | — | — | US | claimed |
| US-20250213523-A1 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) | 2025-07-03 | — | — | US | claimed |
| CN-116751199-B | Mitochondrial protease targeted chimera, preparation method and application | 中国科学院基础医学与肿瘤研究所(筹) | 2025-03-18 | — | — | CN | claimed |
| US-20250009779-A1 | METHODS FOR TREATING VIRAL DISEASES | NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY | 2025-01-09 | — | — | US | claimed |
| US-20240415791-A1 | Therapeutic methods and compositions for treating cancer using devimistat and a fatty acid oxidation inhibitor, a tyrosine kinase inhibitor, a glutaminase inhibitor, and/or a glycolysis inhibitor | CORNERSTONE PHARMACEUTICALS INC (US) | 2024-12-19 | — | — | US | claimed |
| WO-2024196137-A1 | USE OF PDH INHIBITOR FOR TREATING NEUROPATHY | 동아대학교 산학협력단 | 2024-09-26 | — | — | WO | claimed |
| WO-2019204251-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING PROSTATE CANCER USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID | RAFAEL PHARMACEUTICALS, INC. (US) | 2019-10-24 | — | — | WO | claimed |
| US-10391177-B2 | Methods for treating cancer using 6,8-bis (benzylthio) octanonic acid | RAFAEL PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | claimed |
| US-20190177411-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-06-13 | — | — | US | claimed |
| EP-3493818-A1 | METHODS OF DETECTING AND TREATING A TUMOR EXPRESSING PT346 PDK1 | The Wistar Institute Of Anatomy And Biology (US) | 2019-06-12 | — | — | EP | claimed |
| US-20190110993-A1 | Solid Nanoparticle Formulation of Water Insoluble Pharmaceutical Substances with Reduced Ostwald Ripening | SELVARAJ RAJ (US) | 2019-04-18 | — | — | US | claimed |
| WO-2019055525-A1 | SOLID NANOPARTICLE FORMULATION OF WATER INSOLUBLE PHARMACEUTICAL SUBSTANCES WITH REDUCED OSTWALD RIPENING | SELVARAJ RAJ (US) | 2019-03-21 | — | — | WO | claimed |
| US-20190015512-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | CORNERSTONE PHARMACEUTICALS, INC. | 2019-01-17 | — | — | US | claimed |
| WO-2018031407-A1 | METHODS OF DETECTING AND TREATING A TUMOR EXPRESSING PT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-02-15 | — | — | WO | claimed |
| WO-2011143590-A1 | COMBINATION THERAPY COMPOSITIONS AND METHODS USING LIPOIC ACID DERIVATIVES AND AN ANTI-PROLIFERATION AGENT | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2011-11-17 | — | — | WO | claimed |
| US-20100190858-A1 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives | RAFAEL PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391177-B2 | Methods for treating cancer using 6,8-bis (benzylthio) octanonic acid | ALOX15B, ALOX5, SLC25A21 | CYP2C19 765/4885MAPT 4084/4885RXFP1 4270/4885 |
| US-20240415791-A1 | Therapeutic methods and compositions for treating cancer using devimistat and a fatty acid oxidation inhibitor, a tyrosine kinase inhibitor, a glutaminase inhibitor, and/or a glycolysis inhibitor | PDK4, PDK2, PDK1 | CYP2C19 807/4885MAPT 3020/4885RXFP1 4206/4885 |
| US-20100190858-A1 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives | SLC25A1, SLC25A21, SLC25A11 | CYP2C19 500/4885MAPT 2395/4885RXFP1 4531/4885 |
| US-20250009779-A1 | METHODS FOR TREATING VIRAL DISEASES | NFATC1, EIF2AK2, MAVS | CYP2C19 4370/4885MAPT 679/4885RXFP1 4243/4885 |
| US-20190015512-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | SLC25A1, SLC25A21, SLC25A11 | CYP2C19 500/4885MAPT 2395/4885RXFP1 4531/4885 |
| US-20190177411-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | PDK1, PDK2, PCK2 | CYP2C19 4864/4885MAPT 4064/4885RXFP1 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.